Home > Boards > Free Zone > Health and Sciences > Biotech Values

Re: The New Battle Lines in HIV (MRK Isentress)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile DewDiligence Member Level 
Saturday, July 25, 2009 1:52:32 AM
Re: DewDiligence post# 81047 Post # of 161643 
Re: The New Battle Lines in HIV (MRK Isentress)

In addition to the drawback of being dosed BID in a qD world, Isentress is evidently uncompetitive with other first-line HIV drugs on price. According to this PR from the AIDS Healthcare Foundation (an advocacy group for AIDS patients), the yearly price of Isentress for self-pay patients is $12,900* (~$35/day). This is about 3x the price of other commonly used first-line agents and it is additive to the prices of the other two drugs first-line patients must take as part of a 3-drug cocktail:

http://finance.yahoo.com/news/AHF-Renews-Challenge-to-Merck-bw-3048813737.html?x=0&.v=1

*When reimbursed under the Ryan White program, the yearly price is $8,100.



“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist